1. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (S.D.S., A.M.S.).
2. Assistance Publique – Hôpitaux de Paris, National Reference Center for FAP, CHU Bicêtre, INSERM U1195, Université Paris Sud, Le Kremlin-Bicêtre, France (D.A.).
3. Department of Cardiology, University of Heidelberg, Germany (A.K.).
4. Mayo Clinic, Rochester, MN (M.G.).
5. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico (A.G.-D.).
6. Department of Medicine/Cardiology, Columbia University Medical Center, New York, NY (M.S.M.).
7. Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy (G.M.).
8. French Referral Center for Cardiac Amyloidosis, Amyloidosis Mondor Network, GRC Amyloid Research Institute, Department of Cardiology, Assistance Publique – Hôpitaux de Paris, CHU Henri Mondor, and INSERM U955, Clinical Investigation Center, and DHU ATVB, Creteil, France (T.D.).
9. Hôpital Bichat, Cardiology Department, Université Paris Sud, Paris, France (M.S.S.).
10. Neurology Department, Columbia University, College of Physicians and Surgeons, New York, NY (T.H.B.).
11. Division of Hematology, Mayo Clinic, Rochester, MN (A.D.).
12. Amyloidosis Center, Boston Medical Center, MA (J.L.B.).
13. Alnylam Pharmaceuticals, Cambridge, MA (P.G., A.V., V.K., J.C., J.G., J.V.).
14. Department of Public Health and Clinical Medicine, Umeå University, Sweden (O.S.).